BioLineRx Ltd. 最大收入来源是 Oncology and Hematology,在最近的收益报告中收入为 4,070,087。就地区而言, United States 是 BioLineRx Ltd. 的主要市场,收入为 4,070,087。
BioLineRx Ltd. 是否盈利?
否,根据最新的财务报表,BioLineRx Ltd. 的净亏损为 $0
BioLineRx Ltd. 有负债吗?
否,BioLineRx Ltd. 的负债为 0
BioLineRx Ltd. 的流通股有多少?
BioLineRx Ltd. 的总流通股为 0
关键数据
前收盘价
$3.02
开盘价
$3.02
当日区间
$3.02 - $3.32
52周范围
$2.15 - $5.06
交易量
7.7K
平均成交量
50.9K
股息收益率
--
每股收益(TTM)
0.00
市值
$13.7M
什么是 BioLineRx Ltd.?
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The company is headquartered in Modiin, Central(Hamerkaz) and currently employs 24 full-time employees. The company went IPO on 2007-01-30. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.